6 investors discuss why AI is more than just a buzzword in biotech • ProWellTech

As ChatGPT has so aptly demonstrated, AI is now truly entering the mainstream consciousness. That's why we weren't very surprised when a slew of investors told us they rarely see a biotech startup that doesn't incorporate AI in some form or other these days.

"Most of the companies we have seen have an AI component to support the discovery or development processes," Francisco Dopazo, a general partner at Humboldt Fund told ProWellTech recently.

But despite becoming quite the buzzword, AI's apparent ubiquity in biotech isn't actually driving deal flow or higher valuations. So to get a better idea of how ...